Cite

HARVARD Citation

    Meng, Z. et al. (2021). The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report. Cancer biology & therapy. 22 (1), pp. 1-4. [Online]. 
  
Back to record